• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    7/3/23 1:37:59 PM ET
    $BACK
    $BXRX
    $DERM
    $ENSC
    Medical Specialities
    Health Care
    Misc Health and Biotechnology Services
    Health Care
    Get the next $BACK alert in real time by email

    Gainers

    • SQZ Biotechnologies (NYSE:SQZ) shares increased by 68.1% to $0.45 during Monday's regular session. The current volume of 30.0 million shares is 44863.5% of SQZ Biotechnologies's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $13.3 million.
    • Nymox Pharmaceutical (NASDAQ:NYMX) shares rose 31.68% to $0.25. Nymox Pharmaceutical's stock is trading at a volume of 3.3 million shares as of 13:37 EST. This is 5697.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.8 million.
    • Ensysce Biosciences (NASDAQ:ENSC) shares increased by 31.11% to $2.36. Trading volume for Ensysce Biosciences's stock is 11.1 million as of 13:37 EST. This is 1720.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.8 million.
    • IMAC Hldgs (NASDAQ:BACK) shares increased by 27.63% to $0.14. Trading volume for IMAC Hldgs's stock is 40.4 million as of 13:37 EST. This is 1456.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.6 million.
    • Journey Medical (NASDAQ:DERM) stock increased by 23.27% to $1.96. As of 13:37 EST, Journey Medical's stock is trading at a volume of 488.0K, which is 502.3% of its average full-day volume over the last 100 days. The company's market cap stands at $35.5 million.
    • Ventyx Biosciences (NASDAQ:VTYX) shares moved upwards by 23.07% to $40.37. Ventyx Biosciences's stock is trading at a volume of 3.0 million shares as of 13:37 EST. This is 378.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.3 billion.

    Losers

    • Protagonist Therapeutics (NASDAQ:PTGX) stock declined by 19.7% to $22.18 during Monday's regular session. The current volume of 7.5 million shares is 674.2% of Protagonist Therapeutics's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $1.2 billion.
    • Xtant Medical Hldgs (AMEX:XTNT) shares fell 16.32% to $0.78. Trading volume for this security as of 13:37 EST is 82.6K, which is 444.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $84.7 million.
    • Baudax Bio (NASDAQ:BXRX) shares decreased by 14.63% to $1.0. As of 13:37 EST, Baudax Bio's stock is trading at a volume of 7.1 million, which is 262.6% of its average full-day volume over the last 100 days. The company's market cap stands at $6.0 million.
    • Icosavax (NASDAQ:ICVX) shares declined by 14.51% to $8.49. Trading volume for this security as of 13:37 EST is 371.6K, which is 172.1% of its average full-day volume over the last 100 days. The company's market cap stands at $351.7 million.
    • Omega Therapeutics (NASDAQ:OMGA) shares decreased by 14.47% to $4.79. Omega Therapeutics's stock is trading at a volume of 234.2K shares as of 13:37 EST. This is 147.3% of its average full-day volume over the last 100 days. The company's market cap stands at $263.5 million.
    • Laboratory Corp (NYSE:LH) stock declined by 13.38% to $209.05. Trading volume for this security as of 13:37 EST is 882.5K, which is 147.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $18.5 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BACK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BACK
    $BXRX
    $DERM
    $ENSC

    CompanyDatePrice TargetRatingAnalyst
    Ventyx Biosciences Inc.
    $VTYX
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    Protagonist Therapeutics Inc.
    $PTGX
    9/17/2025$72.00Overweight
    Barclays
    Protagonist Therapeutics Inc.
    $PTGX
    9/12/2025$73.00Outperform
    Leerink Partners
    Journey Medical Corporation
    $DERM
    8/25/2025$13.00Buy
    H.C. Wainwright
    Journey Medical Corporation
    $DERM
    7/30/2025$12.00Buy
    B. Riley Securities
    Labcorp Holdings Inc.
    $LH
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    Protagonist Therapeutics Inc.
    $PTGX
    6/17/2025$72.00Buy
    Citigroup
    Labcorp Holdings Inc.
    $LH
    4/2/2025$276.00Buy
    Redburn Atlantic
    More analyst ratings

    $BACK
    $BXRX
    $DERM
    $ENSC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ventyx Biosciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Ventyx Biosciences from Neutral to Buy and set a new price target of $18.00

    11/5/25 7:25:28 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Protagonist Therapeutics with a new price target

    Barclays initiated coverage of Protagonist Therapeutics with a rating of Overweight and set a new price target of $72.00

    9/17/25 8:03:08 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Protagonist Therapeutics with a new price target

    Leerink Partners initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $73.00

    9/12/25 7:52:34 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BXRX
    $DERM
    $ENSC
    SEC Filings

    View All

    SEC Form 15-12G filed by Ventyx Biosciences Inc.

    15-12G - Ventyx Biosciences, Inc. (0001851194) (Filer)

    3/16/26 12:48:18 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Ventyx Biosciences Inc.

    EFFECT - Ventyx Biosciences, Inc. (0001851194) (Filer)

    3/9/26 12:15:03 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Ventyx Biosciences Inc.

    EFFECT - Ventyx Biosciences, Inc. (0001851194) (Filer)

    3/9/26 12:15:04 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BXRX
    $DERM
    $ENSC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Schechter Adam H sold $2,437,047 worth of shares (8,705 units at $279.96), decreasing direct ownership by 10% to 80,773 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    3/5/26 8:57:09 AM ET
    $LH
    Medical Specialities
    Health Care

    Senior VP, Finance Gonzales Roy returned 5,313 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    3/4/26 4:38:03 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Subramaniam Somu returned 3,337,495 shares to the company (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    3/4/26 4:35:10 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BXRX
    $DERM
    $ENSC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ruiz Jorge bought $3 worth of shares (1 units at $2.69), increasing direct ownership by 0.00% to 141,230 units (SEC Form 4)

    4 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/18/25 12:01:15 PM ET
    $BACK
    Medical Specialities
    Health Care

    Large owner Ruiz Jorge bought $590,192 worth of shares (164,872 units at $3.58) and sold $39,955 worth of shares (16,487 units at $2.42) (SEC Form 4)

    4 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/14/25 3:43:49 PM ET
    $BACK
    Medical Specialities
    Health Care

    Director Gujrathi Sheila bought $300,573 worth of shares (130,000 units at $2.31) (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    12/26/24 8:05:18 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BXRX
    $DERM
    $ENSC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Xtant Medical Finalizes Companion Spine Transactions

    Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it has received $10.7 million from Companion Spine related to Companion Spine's purchase of Xtant's Coflex® assets and Paradigm OUS businesses in December 2025, bringing the total aggregate purchase price for the two divestitures to $21.4 million. With this payment, the transactions have now been finalized.

    3/2/26 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

    Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal Study Submission Primarily Based on Phase 3 VERIFY Study, in Which Rusfertide Plus Standard of Care More Than Doubled Clinical Response Rates, as Well as Four-Year Efficacy and Safety Data from Phase 2 REVIVE/THRIVE Studies Prescription Drug User Fee Act (PDUFA) Target Action Date is in the Third Quarter of this Calendar Year Takeda ((TAK) and Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted

    3/2/26 2:00:00 AM ET
    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BXRX
    $DERM
    $ENSC
    Leadership Updates

    Live Leadership Updates

    View All

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

    BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical r

    2/9/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Appoints Victor Bulto to Board of Directors

    Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025. Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leadin

    11/24/25 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $BACK
    $BXRX
    $DERM
    $ENSC
    Financials

    Live finance-specific insights

    View All

    Labcorp Announces 2025 Fourth Quarter and Full Year Results

    Company Provides 2026 GuidanceFinancial results from Operations versus 2024:Revenue: Q4 of $3.52 billion vs $3.33 billion; Full year of $13.95 billion vs $13.01 billionDiluted EPS: Q4 of $1.98 vs $1.70; Full year of $10.46 vs $8.84Adjusted EPS: Q4 of $4.07 vs $3.45; Full year of $16.44 vs $14.57Free Cash Flow: Q4 of $490.3 million vs. $665.1 million; Full year of $1.21 billion vs $1.10 billionProvided Full-Year 2026 Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4%Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9%Free Cash Flow of $1.24 billion to $1.36 billion; midpoint growth of 7.8%Expanded partnerships

    2/17/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026

    BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici

    1/15/26 4:15:00 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Declares Quarterly Dividend

    BURLINGTON, N.C., Jan. 14, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and c

    1/14/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $BACK
    $BXRX
    $DERM
    $ENSC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care